Qiaoye Qing Powder Veterinary Grade API is distributed as a multi-component dry powder for use in oral and parenteral veterinary drug product manufacturing. It is not sold as a sterile product; sterile terminal dosage forms must undergo site-specific sterilization or aseptic processing. Release documentation includes loss on drying by USP <731>, particle size distribution by ISO 13320:2020, sulfated ash by current Chinese Veterinary Pharmacopoeia general chapter 0802, and elemental impurity screening by USP <232>/<233>. The downstream application scenarios below are restricted to industrial processes corresponding to the supplied dosage form list: tablets, injections, capsules, powders, granules, premix, and solutions.

In oral tablet compression for swine and poultry, the API is first dry-blended with microcrystalline cellulose PH-102, croscarmellose sodium at 2–5% w/w, and sodium starch glycolate at 1–3% w/w. The mixture is passed through a 0.8-mm oscillating sieve before direct compression on a 27-station rotary tablet press. The addition ratio of Qiaoye Qing Powder Veterinary Grade API in the uncoated core is set between 20% and 45% w/w; the upper limit is not a fixed solubility boundary but a powder flow boundary because the Carr index derived from USP <616> exceeds 28% when untreated API is present above that band. Main compression force is maintained at 10–18 kN, precompression force at 25–35% of main force, and press speed at 60–100 rpm. Punch sticking is observed when residual moisture is above 4.5% LOD; therefore the compression suite is conditioned to 18–25°C and 35–50% RH, and lots above 5.0% LOD are pre-dried in a forced-air tray dryer at 40–50°C until ≤ 4.0% LOD. Magnesium stearate is limited to 0.75% w/w and blended for 3–5 min to avoid delayed disintegration; disintegration is tested by USP <701>, uniformity of dosage units by USP <905>, and dissolution by USP <711> when the product monograph includes a dissolution procedure. The terminal product type is a film-coated or uncoated oral tablet packed in aluminum/aluminum blister cavities. Finished product release falls under the current Chinese Veterinary Pharmacopoeia tablet monograph and local veterinary GMP.

What limits sterile filtration of injectable solutions containing the API?

Injectable solution manufacture begins with dissolution of the API in Water for Injection at 20–30°C in 316L stainless-steel mixing tanks under nitrogen sparging. The API concentration is screened from 1% to 5% w/v for true solutions, while suspension injections are milled to a D90 ≤ 10 µm by ISO 13320:2020 and formulated up to 10% w/v. Sterile filtration is performed by a 0.45-µm clarifying membrane followed by a 0.22-µm polyethersulfone membrane. A throughput decline of more than 30% over the first 200 L indicates colloid loading and requires additional centrifugal clarification or a second clarification stage before sterilizing filtration. The pH is adjusted with dilute hydrochloric acid or sodium hydroxide and held within ±0.2 pH units of the dossier target because larger excursions alter the ionization state of marker constituents and reduce recovery by liquid chromatography. In-process bioburden is controlled below 10 CFU/100 mL before the final filter. The finished solution is filled under EU GMP Annex 1 conditions into Type II amber vials; if thermal stability data support it, terminal sterilization is applied at 121°C for 15 min. Particulate matter is checked by USP <788> and visible particulate inspection by USP <790>. The terminal product type is a sterile aqueous injection in 50-mL or 100-mL Type II glass vials with bromobutyl stoppers. Residual solvents, if present from any co-solvent, are limited by VICH GL18.

During medicated feed premix blending for swine and poultry feed mills, the API is first combined with 1–3 kg of milled rice hull or lactose carrier per kg API in a low-shear ribbon mixer. This first-stage trituration prevents the powder from floating and segregating when charged into a 2000-kg horizontal ribbon mixer. Premix addition ratio is screened between 0.5 kg and 5.0 kg API per metric ton of complete feed equivalent; the final complete feed inclusion is typically 0.05–0.5% w/w depending on the approved target species dose. Homogeneity testing uses at least 10 sampling points across the mixer discharge with an assay coefficient of variation below 5.0%; the standard mixer run time is 12–15 min, but the final validated mix time is set by tracer assay, not by fixed equipment settings. The main mixer and conveyors should comply with 21 CFR 225.1 for medicated feed facilities and 21 CFR 226.58 for finished medicated feed inspection. Terminal product type is a 25-kg multi-wall paper bag with an inner 0.1-mm polyethylene liner containing a medicated premix for on-farm or licensed feed mill incorporation. If the API lot has moisture above 5.0%, it is dried before trituration because damp API bridges at the carrier junction and raises mix CV beyond 5.0%.

When drinking-water solubility falls below 1 g/L, wet granulation becomes the limiting step

Oral granules and drinking-water powders are produced by top-spray fluidized-bed granulation when the API dispersed in water yields a solubility below 1 g/L as measured by the site's approved solubility assay. The API is loaded at 25–50% w/w of the dry granule basis. A binder solution of povidone K30 at 3–5% w/w of dry solids is sprayed at 8–12 g/min/kg bed mass with inlet air temperature 55–65°C and bed temperature maintained at 35–42°C; finished granule moisture is controlled to 2.0–3.5% by USP <731>. Particle size is monitored by sieve analysis at 0.150 mm, and oversize material is dry-milled in a low-shear mill fitted with a 1.0-mm screen. The reconstituted drinking-water concentration is normally 0.5–2.0 g/L, with the lower range used for in-feed or water administration and the upper range reserved for short-term use according to the approved veterinary product file; a fixed generic addition rate is not applicable. The final powder or granule is packed in 100-g, 500-g, or 1-kg aluminum-lined sachets. Release testing includes loss on drying by USP <731>, uniform dispersion after 5 min stirring at 25°C, and microbial enumeration by USP <2021>. Terminal product type is a reconstitutable oral granule or powder for drinking-water medication.

Static powder bed stratification during capsule filling is controlled by maintaining the API blend within a bulk density band of 0.42–0.58 g/mL and by adding 0.5–1.0% w/w colloidal silicon dioxide. The API fraction in the capsule fill is formulated between 30% and 60% w/w, with the remainder composed of pregelatinized starch, lactose monohydrate, and magnesium stearate at 0.5% w/w. Capsule filling is performed on a 150,000 capsules/h rotary dosator machine with tamping pins set to 30–50 N; split body and defective cap incidence is kept below 0.1%. Fill weight variation is checked by USP <905>, and disintegration by USP <701>. The humidity in the filling suite is held at 25–35% RH and 15–25°C; lots above 3.5% LOD are pre-dried in a vacuum dryer at 40°C until moisture is ≤ 3.5%. The terminal product type is a hard gelatin or hypromellose capsule in blister or HDPE bottle packaging. Powder bridging at the dosator outlet is the primary failure mode on continuous-motion fillers when the blend is over-lubricated; if bridging appears, magnesium stearate is reduced by 0.1% w/w before any change to capsule shell size. Finished capsule products are released under the current Chinese Veterinary Pharmacopoeia capsule monograph or equivalent veterinary formulary standard.

Oral drench solution stability and low-oxygen filling conditions

Oral drench solutions are compounded by dispersing the API in purified water at 5–15% w/v, with xanthan gum at 0.1–0.3% w/w as suspending agent and citrate buffer to hold pH at 4.5–6.0. The preserved system contains methylparaben at 0.18% w/v and propylparaben at 0.02% w/v; alternative preservatives require preservative efficacy testing by USP <51>. The batch is mixed under vacuum at -0.08 MPa to remove entrained air, and dissolved oxygen is reduced to ≤ 1.0 mg/L by nitrogen sparging before filling. The terminal product type is a ready-to-use oral drench suspension or solution filled into high-density polyethylene drench bottles with zero-headspace dosing pumps, in volumes from 100 mL to 1 L. The fill line is operated with a nitrogen overlay and residual headspace below 2% of bottle volume to limit oxidative degradation of marker constituents. Release testing includes pH by USP <791>, viscosity by a rotational viscometer at 25°C, redispersibility after 30 s manual shaking, and stability under VICH GL3 storage conditions. Operational boundary: the drench should not be exposed to direct sunlight for more than 24 h during warehouse staging because light-sensitive marker compounds may degrade; amber or white opaque high-density polyethylene bottles are therefore specified over clear containers.